| Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study GK Abou-Alfa, V Sahai, A Hollebecque, G Vaccaro, D Melisi, R Al-Rajabi, ... The Lancet Oncology 21 (5), 671-684, 2020 | 1185 | 2020 |
| Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology AB Benson, MI D’Angelica, DE Abbott, DA Anaya, R Anders, C Are, ... Journal of the National Comprehensive Cancer Network 19 (5), 541-565, 2021 | 593 | 2021 |
| Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial MJ Pishvaian, EM Blais, JR Brody, E Lyons, P DeArbeloa, A Hendifar, ... The Lancet Oncology 21 (4), 508-518, 2020 | 405 | 2020 |
| NCCN guidelines insights: hepatobiliary cancers, version 1.2017 AB Benson, MI D'Angelica, DE Abbott, TA Abrams, SR Alberts, DA Anaya, ... Journal of the National Comprehensive Cancer Network 15 (5), 563-573, 2017 | 329 | 2017 |
| Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation EM O’Reilly, JW Lee, M Zalupski, M Capanu, J Park, T Golan, E Tahover, ... Journal of Clinical Oncology 38 (13), 1378-1388, 2020 | 322 | 2020 |
| Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma EJ Kim, V Sahai, EV Abel, KA Griffith, JK Greenson, N Takebe, GN Khan, ... Clinical cancer research 20 (23), 5937-5945, 2014 | 302 | 2014 |
| Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma E Van Cutsem, MA Tempero, D Sigal, DY Oh, N Fazio, T Macarulla, ... Journal of Clinical Oncology 38 (27), 3185, 2020 | 284 | 2020 |
| NCCN guidelines insights: Hepatobiliary cancers, version 2.2019: Featured updates to the NCCN guidelines AB Benson, MI D’Angelica, DE Abbott, TA Abrams, SR Alberts, DA Anaya, ... Journal of the National Comprehensive Cancer Network 17 (4), 302-310, 2019 | 256 | 2019 |
| Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer NG Steele, ES Carpenter, SB Kemp, VR Sirihorachai, S The, L Delrosario, ... Nature Cancer 1 (11), 1097-1112, 2020 | 251 | 2020 |
| Metastatic pancreatic cancer: ASCO guideline update DPS Sohal, EB Kennedy, P Cinar, T Conroy, MS Copur, CH Crane, ... Journal of Clinical Oncology 38 (27), 3217-3230, 2020 | 207 | 2020 |
| Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma AF Buckley, LJ Burgart, V Sahai, S Kakar American journal of clinical pathology 129 (2), 245-251, 2008 | 190 | 2008 |
| GM-CSF mediates mesenchymal–epithelial cross-talk in pancreatic cancer M Waghray, M Yalamanchili, M Dziubinski, M Zeinali, M Erkkinen, H Yang, ... Cancer discovery 6 (8), 886-899, 2016 | 175 | 2016 |
| Dose escalation trial of the Wee1 inhibitor adavosertib (AZD1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer KC Cuneo, MA Morgan, V Sahai, MJ Schipper, LA Parsels, JD Parsels, ... Journal of Clinical Oncology 37 (29), 2643, 2019 | 147 | 2019 |
| Assessment of clinical benefit of integrative genomic profiling in advanced solid tumors EF Cobain, YM Wu, P Vats, R Chugh, F Worden, DC Smith, SM Schuetze, ... JAMA oncology 7 (4), 525-533, 2021 | 133 | 2021 |
| Tumour-reprogrammed stromal BCAT1 fuels branched-chain ketoacid dependency in stromal-rich PDAC tumours Z Zhu, A Achreja, N Meurs, O Animasahun, S Owen, A Mittal, P Parikh, ... Nature Metabolism 2 (8), 775-792, 2020 | 120 | 2020 |
| Clinicopathologic Characteristics, CpG Island Methylator Phenotype, and BRAF Mutations in Microsatellite-Stable Colorectal Cancers Without Chromosomal … S Kakar, G Deng, V Sahai, K Matsuzaki, H Tanaka, S Miura, YS Kim Archives of pathology & laboratory medicine 132 (6), 958-964, 2008 | 119 | 2008 |
| Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial V Sahai, PJ Catalano, MM Zalupski, SJ Lubner, MR Menge, HS Nimeiri, ... Jama Oncology 4 (12), 1707-1712, 2018 | 115 | 2018 |
| Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart … JR Strosberg, AB Benson, L Huynh, MS Duh, J Goldman, V Sahai, ... The oncologist 19 (9), 930-936, 2014 | 115 | 2014 |
| High-throughput microfluidic labyrinth for the label-free isolation of circulating tumor cells E Lin, L Rivera-Báez, S Fouladdel, HJ Yoon, S Guthrie, J Wieger, Y Deol, ... Cell systems 5 (3), 295-304. e4, 2017 | 111 | 2017 |
| Targeting BET bromodomain proteins in solid tumors V Sahai, AJ Redig, KA Collier, FD Eckerdt, HG Munshi Oncotarget 7 (33), 53997, 2016 | 104 | 2016 |
Kent A GriffithCenter for Cancer Biostatistics, University of Michigan School of Public HealthAdresse e-mail validée de med.umich.edu
